Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21119415 | 0.86 | L3MBTL1 (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29074073 | 0.84 | ESR1 (0.42) | CYP3A4TSHRALDH1A1LMNASLC6A4 | |
| SCHEMBL1240135 | 0.83 | SMN1; SMN2 (0.44) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28784720 | 0.82 | KCNN4 (0.58) | MEN1KMT2ACYP2C19NPSR1TSHR | |
| SCHEMBL4701609 | 0.81 | MEN1 (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2262869 | 0.81 | CYP3A4 (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7097465 | 0.80 | MIF (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1978095 | 0.78 | POLB (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6825088 | 0.78 | POLB (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2260444 | 0.77 | GRIN2D (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6593355-B2 | 2-phenylaminomethyl benzimidazole derivatives | BOEHRINGER INGELEHIM PHARMA KG (DE) | 2003-07-15 | — | — | US | disclosed |
| US-20030004356-A1 | Benzimidazoles with antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-02 | — | — | US | disclosed |
| EP-1095025-B1 | BENZIMIDAZOLES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1244636-A1 | BENZIMIDAZOLES, PRODUCTION THEREOF AND THE USE THEREOF AS ANTITHROMBOTIC | Boehringer Ingelheim Pharma KG (DE) | 2002-10-02 | — | — | EP | disclosed |
| US-6451832-B2 | E.G., 2-(AMINDINOPHENYLAMINOMETHYL)-1-METHYL-5-(1-(ETHOXY-CARBONYL-METHYLAMINO)-1 -(2,5-DIHYDROPYRROLOCARBONYL)-ETHYL)BENZIMIDAZOLE; ANTICOAGULANTS AND ANTITHROMBOLYTIC AGENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-09-17 | — | — | US | disclosed |
| WO-2001047896-A1 | BENZIMIDAZOLES, PRODUCTION THEREOF AND THE USE THEREOF AS ANTITHROMBOTIC | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-07-05 | — | — | WO | disclosed |
| US-20010006977-A1 | Benzimidazoles with antithrombotic activity | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2001-07-05 | — | — | US | disclosed |
| US-6248770-B1 | CARDIOVASCULAR DISORDERS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-06-19 | — | — | US | disclosed |
| EP-1095025-A2 | BENZIMIDAZOLES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM KG (DE) | 2001-05-02 | — | — | EP | disclosed |
| US-6200976-B1 | FOR TREATING THROMBOSIS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-03-13 | — | — | US | disclosed |
| EP-1071669-A1 | BICYCLIC COMPOUNDS HAVING AN ANTI-THROMBITIC EFFECT | Boehringer Ingelheim Pharma KG (DE) | 2001-01-31 | — | — | EP | disclosed |
| WO-2000001704-A2 | BENZIMIDAZOLES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999054313-A1 | BICYCLIC COMPOUNDS HAVING AN ANTI-THROMBITIC EFFECT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004356-A1 | Benzimidazoles with antithrombotic activity | SERPINC1, SERPINB1, PF4 | GRIN2D 3587/4885GRIN3B 2375/4885GRIN1 2013/4885 |
| US-20010006977-A1 | Benzimidazoles with antithrombotic activity | SERPINC1, SERPINB1, PF4 | GRIN2D 3587/4885GRIN3B 2375/4885GRIN1 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.